RxDoctor Payments Data

Jillian Grzegorczyk

Family · Muskegon, MINPI 1942789805

Payments from drug & device makers

$2,298in general payments, 2019–2025

Across 79 payments — averaging $29.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$299
  • AstraZeneca$287
  • Abbott$263
  • Novartis$237
  • Johnson & Johnson$176
  • E.r. Squibb & Sons, L.L.C.$139
  • plus $897 from 19 others

What the payments were for

  • Food & beverage$2,22397%
  • Education$753%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,298 in reported general payments places this provider in the 85th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$20,390
Medicare patients
161
Services billed
268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin127$144,885
EntrestoSacubitril/Valsartan100$101,187
FarxigaDapagliflozin Propanediol70$73,604
EliquisApixaban39$44,284
Metoprolol Succinate179$3,995
Spironolactone223$2,356
Isosorbide Mononitrate ErIsosorbide Mononitrate37$873
Carvedilol54$853
Rosuvastatin Calcium31$676
Atorvastatin Calcium42$673
Bumetanide16$634
Furosemide99$595
Amiodarone Hcl24$553
Hydralazine Hcl21$507
Losartan Potassium42$316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$57$144,885127 claims
NovartisEntresto$237$101,187100 claims
AstraZenecaFarxiga$287$73,60470 claims
PfizerEliquis$69$44,28439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,657 family providers in Michigan.

Other family in Muskegon

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →